Lumendo raises CHF 2.54 million to bring its novel endodontic treatment platform to clinical use
17.01.2022
The financing round was led by Dominik Lysek, PhD, partner at US-based Revere Partners. Co-investors were Zürich Cantonal Bank and Business Angels Switzerland. In 2017, Lumendo won Venture Kick and was a Venture Leader Life Sciences.
 The Lumendo co-founders
|
 |
Lumendo CEO, Andreas Schmocker, PhD, commented: “This seed financing round is a major milestone for Lumendo. It allows us to translate our prototypes into a clinical workflow, ultimately moving closer towards the goal of disrupting the endodontic device and consumable market. The clinical proof of concept and validation with a prototype produced under ISO 13485 is the most important milestone on the path of getting market approval for our products, and make Lumendo a success.”
Dominik Lysek, partner at Revere Partners confirmed, that: “being one of the world’s top innovators in the financing of oral health startups, we strongly believe in the potential of Lumendo’s offering of a minimally invasive endodontic treatment solution. We are convinced that by providing faster and more ergonomic procedures, we will improve treatment efficacy and success and thus enable a more reliable patient outcome. The ingenuity of Lumendo’s technology will allow it to penetrate the market quickly and efficiently.”
Because of the high interest, the initially planned size of CHF 1.8 million has been oversubscribed. The Lumendo management and board will accept additional funds until Q1 2022.
The Lumendo co-founders Andreas Schmocker (CEO, left) and Mark Bispinghoff (CTO, right)
Source: Lumendo website (press release and image)
Dominik Lysek, partner at Revere Partners confirmed, that: “being one of the world’s top innovators in the financing of oral health startups, we strongly believe in the potential of Lumendo’s offering of a minimally invasive endodontic treatment solution. We are convinced that by providing faster and more ergonomic procedures, we will improve treatment efficacy and success and thus enable a more reliable patient outcome. The ingenuity of Lumendo’s technology will allow it to penetrate the market quickly and efficiently.”
Because of the high interest, the initially planned size of CHF 1.8 million has been oversubscribed. The Lumendo management and board will accept additional funds until Q1 2022.
The Lumendo co-founders Andreas Schmocker (CEO, left) and Mark Bispinghoff (CTO, right)
Source: Lumendo website (press release and image)